Calidi Biotherapeutics Beheer

Beheer criteriumcontroles 4/4

De CEO Calidi Biotherapeutics is Allan Camaisa, benoemd in Feb2018, heeft een ambtstermijn van 6.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 436.51K, bestaande uit 58.9% salaris en 41.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.4% van de aandelen van het bedrijf, ter waarde $ 148.05K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.8 jaar en 3.8 jaar.

Belangrijke informatie

Allan Camaisa

Algemeen directeur

US$436.5k

Totale compensatie

Percentage CEO-salaris	58.9%
Dienstverband CEO	6.8yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	6.8yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Allan Camaisa's beloning veranderd ten opzichte van Calidi Biotherapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$437k	US$257k	-US$29m
Sep 30 2023	n/a	n/a	-US$29m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$24m
Dec 31 2022	US$2m	US$43k	-US$25m
Sep 30 2022	n/a	n/a	-US$21m
Dec 31 2021	US$1m	US$26k	-US$11m

Compensatie versus markt: De totale vergoeding ($USD 436.51K ) Allan } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: De vergoeding van Allan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Allan Camaisa (64 yo)

6.8yrs

Tenure

US$436,512

Compensatie

Mr. Allan J. Camaisa serves as Chief Executive Officer and Chairman of the Board at Calidi Biotherapeutics, Inc since February 2018. He served as Chief Executive Officer and Chairman at Parallel 6, Inc. si...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Allan Camaisa	CEO & Chairman of the Board	6.8yrs	US$436.51k	0.40% $ 148.1k
Wendy Pizarro Campbell	Chief Administrative Officer	3.2yrs	US$295.40k	0.084% $ 31.3k
Boris Minev	President of Medical & Scientific Affairs and Interim Chief Medical Officer	9.4yrs	US$400.10k	0.22% $ 81.9k
Andrew Jackson	Chief Financial Officer	1.1yrs	geen gegevens	geen gegevens
Stephen Thesing	Chief Business Officer	8.8yrs	geen gegevens	0.24% $ 91.0k

6.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CLDI is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Allan Camaisa	CEO & Chairman of the Board	6.8yrs	US$436.51k	0.40% $ 148.1k
James Schoeneck	Independent Director	4.3yrs	US$109.56k	0.53% $ 197.4k
W.K. Yung	Member of Medical Advisory Board	2.4yrs	geen gegevens	geen gegevens
Ewa Carrier	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
George Peoples	Independent Director	less than a year	geen gegevens	0.00089% $ 331.8
Scott Leftwich	Independent Vice-Chairman of the Board	5.5yrs	US$179.89k	1.23% $ 459.1k
Alan Stewart	Independent Director	1.1yrs	US$120.56k	0.029% $ 10.7k
Santosh Kesari	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Dmitriy Zamarin	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
Ashok Srivastava	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Karen Aboody	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Maciej Lesniak	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CLDI wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Calidi Biotherapeutics Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Recent updates

Calidi Biotherapeutics Inc. Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.499999 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting

New major risk - Financial position

New major risk - Market cap size

New major risk - Revenue and earnings growth

Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Less than half of directors are independent

Calidi Biotherapeutics Announces Directorate Changes

Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board

New major risk - Financial position

New major risk - Shareholder dilution

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer

Less than half of directors are independent

Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. announced that it has received funding from Jackson Investment Group, Calidi Cure, LLC

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd